Hollield Carmen, Amara Shivkar, M Lewin Jesse, G Lebwohl Mark
J Drugs Dermatol. 2025 Mar 1;24(3):329-331. doi: 10.36849/JDD.8329.
Neoadjuvant Hedgehog Pathway Inhibitor (HPI) therapy, utilizing sonidegib and vismodegib, has shown great potential in managing locally advanced basal cell carcinoma (laBCC). While effective, the tolerability of HPI therapy may be limited due to adverse effects (muscle spasms, alopecia). However, studies have shown a lower incidence of side effects with sonidegib, compared to vismodegib. In this report, we present the case of an 86-year-old male with laBCC on the left inner canthus treated successfully with neoadjuvant sonidegib for 25 weeks prior to Mohs micrographic surgery. This case highlights the utility of sonidegib as a potential neoadjuvant treatment modality for patients who are good candidates for surgery but would benefit from tumor reduction to achieve a more favorable outcome, especially in cosmetically sensitive areas. In addition, our patient experienced minimal side effects (muscle cramps at week 18) from sonidegib treatment. J Drugs Dermatol. 2025;24(3):329-331. doi:10.36849/JDD.8329.
新辅助刺猬通路抑制剂（HPI）疗法，使用索尼德吉和维莫德吉，在治疗局部晚期基底细胞癌（laBCC）方面已显示出巨大潜力。虽然有效，但由于不良反应（肌肉痉挛、脱发），HPI疗法的耐受性可能有限。然而，研究表明，与维莫德吉相比，索尼德吉的副作用发生率较低。在本报告中，我们介绍了一名86岁男性患者的病例，该患者左内眦患有laBCC，在莫氏显微外科手术前接受了25周的新辅助索尼德吉治疗并取得成功。该病例突出了索尼德吉作为一种潜在新辅助治疗方式的效用，对于那些适合手术但会从肿瘤缩小中获益以获得更有利结果的患者，尤其是在美容敏感区域。此外，我们的患者在接受索尼德吉治疗时出现的副作用最小（第18周出现肌肉痉挛）。《药物皮肤病学杂志》。2025年；24（3）：329 - 331。doi:10.36849/JDD.8329。
